# Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT01900665
- Published: 2013-07-16
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01900665
- Source URL: https://clinicaltrials.gov/study/NCT01900665
- Provenance: clinicaltrials

## Abstract

To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: EXPEDITION 3
- status: TERMINATED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 2129
- sponsor: Eli Lilly and Company
- conditions: Alzheimer's Disease
- interventions: DRUG: Solanezumab; DRUG: Placebo
- start date: 2013-07-01
- primary completion date: 2016-10-01
- has results: true
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.